Articles tagged with Attention Deficit Hyperactivity Disorder
A post hoc analysis of Phase 3 study data found that Vyvanse significantly improved emotional lability composite CPRS-RS scores in children with ADHD aged 6 to 12 years. Treatment with Vyvanse yielded significant improvements in emotional lability scores only for those with prominent emotional lability prior to treatment.
A Phase IIIb study of Daytrana found significant improvements in ADHD symptoms in adolescents aged 13-17 years, with most adverse events mild to moderate. Pharmacokinetic data also showed similar exposure to d-MPH in both children and adolescents.
INTUNIV demonstrated significant efficacy in reducing symptoms of attention deficit hyperactivity disorder (ADHD), particularly oppositional symptoms, in children and adolescents. The study showed improved symptoms as measured by the Conners' Parent Rating Scale-Revised: Long Form (CPRS-R:L) and ADHD Rating Scale-IV (ADHD-RS-IV).
Shire presents new scientific data on its ADHD portfolio, including INTUNIV, Vyvanse, and Daytrana. The company's ADHD business unit is committed to advancing treatment research and developing safe and effective treatments.
The Canadian Cardiovascular Society has released new guidelines for the management of adults with congenital heart disease, cardiovascular risk evaluation tools, and simplified target levels. The guidelines aim to provide evidence-based medicine for clinicians and improve heart health in Canadians.
A study by IMpACT, an international collaboration of researchers, suggests that adult ADHD has a high genetic component. The findings indicate that multiple gene defects contribute to the disorder, with heritability estimates ranging from 60%. This research aims to identify risk genes for ADHD and develop effective treatments.
A brain-imaging study found that ADHD patients have lower-than-normal dopamine markers, which may underlie symptoms of inattention and reduced motivation. This deficit could lead to complications like drug abuse and obesity.
A study found that Vyvanse significantly reduced ADHD symptoms in children aged 6-12 from 1.5 to 13 hours after taking the medication. The study, published online in Child and Adolescent Psychiatry and Mental Health, demonstrated long-lasting efficacy of Vyvanse in improving behavior and attention.
A study comparing children with FASD and ADHD reveals significant differences in social cognition and emotional processing. Children with FASD show a distinct profile of weaker social skills, including high distractibility and restlessness, which may underlie the severe conduct problems observed in these individuals.
Researchers at Queen's University have created eye movement tests to aid in understanding childhood brain development, healthy aging, and the diagnosis of Attention Deficit Hyperactivity Disorder (ADHD) and Parkinson's disease. The study found that children scored low on these tests, while those with ADHD showed decreased normal brain ...
In a simulated workplace environment study, VYVANSE CII improved ADHD symptoms of inattention, hyperactivity, and impulsivity, as measured by the Permanent Product Measure of Performance (PERMP) and ADHD Rating Scale (ADHD-RS). Adults taking VYVANSE showed significant efficacy at 14 hours after administration.
Pediatric researchers found hundreds of gene variations associated with ADHD, many linked to learning, behavior, and brain function. The study suggests future drug targets and personalized treatments may be possible.
Coadministration of Prilosec OTC 40 mg did not alter maximum plasma concentration or area under curve for active medication in both VYVANSE and ADDERALL XR. The study also found a significant reduction in time to reach maximum plasma concentrations of amphetamine with coadministration of Prilosec OTC 40 mg.
INTUNIV demonstrated significant efficacy in treating ADHD symptoms, particularly in children aged 6-12 years with oppositional behaviors. The study showed improved symptom reduction on various rating scales, including the ADHD Rating Scale-IV and Clinical Global Impressions-Improvement.
Shire plc will present key scientific data on its Attention Deficit Hyperactivity Disorder (ADHD) treatments lisdexamfetamine dimesylate and investigational non-scheduled guanfacine extended release. The presentations include studies on the pharmacokinetics, duration of effects, patient experience, and response to treatment.
Children with high blood pressure are more likely to have learning disabilities and ADHD, with a four-fold increased risk. The study also found that hypertensive children have difficulties in goal-directed tasks and working memory.
A study reveals that adolescents with ADHD are more likely to experience current and lifetime sleep problems and disorders, regardless of ADHD symptom severity. Mental health professionals are advised to screen for sleep problems and psychiatric comorbidities in all adolescents with a childhood ADHD diagnosis.
A recent Finnish study found that short sleep duration increases risk for behavioral symptoms of ADHD, even without sleeping difficulties. The researchers tracked 280 healthy children and found a higher hyperactivity and impulsivity score with shorter sleep duration.
Research published in the Journal of Developmental and Behavioural Pediatrics found that nearly 90% of Tourette syndrome cases exist in conjunction with another disorder, most frequently ADHD. Perinatal factors such as low birth weight, prematurity, and maternal smoking increase the risk of co-occurring ADHD in children with Tourette.
Research shows in-clinic therapy and at-home reinforcement are more effective than home-based programs in treating convergence insufficiency, a condition that affects students' performance in school.
A study by UC Davis M.I.N.D. Institute found that children with ADHD exhibit variable response times during working memory tasks, even when accuracy is similar to typically developing peers. Higher levels of hyperactivity and impulsivity are associated with slower reaction times.
A distinct alpha-wave pattern occurs just before subjects make mistakes on attention-demanding tests, suggesting a potential method for monitoring attention and predicting errors. The discovery could lead to practical applications in air traffic control and new therapies for children with ADHD.
Researchers discovered an abnormality in the brains of adolescent boys with attention deficit hyperactivity disorder, particularly in the anterior cingulate cortex. This region normally activates when a reward stops, but in boys with ADHD, it fails to do so, leading to continued activation and impulsive behavior.
A new University of Central Florida study may explain why children with attention deficit hyperactivity disorder (ADHD) move around a lot. The research found that children with ADHD become significantly more active when required to remember and manipulate computer-generated letters, numbers, and shapes for a short time.
A new study reveals that children with attention deficit/hyperactivity disorder (ADHD) have a shorter total sleep time and reduced rapid eye movement (REM) sleep compared to healthy controls. This intrinsic sleep problem may contribute to the symptoms of ADHD.
Studies find that access to nature reduces aggression, crime rates, and improves cognitive function in children with ADHD. Living near trees also positively influences mood, life satisfaction, and social interactions, particularly among elderly adults.
Two studies examine over 600,000 genetic markers in ADHD patients, finding that multiple genes contribute to the disorder. The findings highlight the need for larger studies to fully understand the genetic mechanisms underlying ADHD and to develop more effective treatments.
A study found Transcendental Meditation (TM) significantly reduced ADHD symptoms, stress, and anxiety among middle school students. TM improved attention, working memory, organization, and behavior regulation, enabling teachers to teach more effectively.
A study of smokers with attention deficit and hyperactivity symptoms found those with elevated hyperactivity and impulsivity showed lower quit rates compared to those with inattention or no A.D.H.D. symptoms.
Researchers at NIH and Duke University Medical Center found no evidence of cytogenetic damage in children taking stimulant medications for ADHD. The study included 63 children aged 6-12 who received either methylphenidate or mixed amphetamine salts, and showed similar results with both treatments.
Researchers have uncovered structural features of the brain that may contribute to the development of ADHD. The study used a new analysis tool to examine shape differences in the brains of children with ADHD and found significant abnormalities in boys, but not girls.
Researchers from the Kennedy Krieger Institute found that girls with ADHD experience fewer motor skill difficulties compared to their male peers. The study suggests that sex-related differences in children with ADHD extend beyond symptom presentation, and that girls may outgrow ADHD-related motor skill deficits before age 7.
Research suggests that ADHD impacts movement control differently in boys and girls, with girls showing better coordination skills despite having the disorder. Girls with ADHD are twice as likely to perform movements typically expected for their age compared to boys with ADHD.
The study found that VYVANSE controlled ADHD symptoms from the first time point measured through the last time point assessed. In addition, VYVANSE treatment was associated with significant improvement in math problems attempted and answered correctly for up to 13 hours post-dose.
Parents of a child with ADHD nearly twice as likely to divorce by age 8 compared to parents without ADHD. Marriages involving children with ADHD ended sooner than those without ADHD.
Young people with ADHD are more likely to become dependent on nicotine and experience environmental factors that increase their risk of smoking. The study found that individuals with more ADHD-related symptoms were at greater risk of nicotine dependence than those with fewer symptoms.
Research conducted at the University of Illinois shows that children with ADHD demonstrate greater attention after a 20-minute walk in a park compared to similar walks in downtown or residential areas. The study found that even small doses of nature exposure can improve symptoms, suggesting a potential long-term benefit.
Researchers found that treatment with stimulant drugs significantly decreased the risk that girls with ADHD will begin smoking cigarettes or using alcohol or drugs. The study's results mirror those of earlier studies in boys and suggest a potential protective effect of stimulant treatment.
LIALDA demonstrated a steady 5-ASA release throughout the entire colon, with prolonged disintegration in the ascending colon. A post hoc analysis also found that patients could achieve complete symptom resolution after up to 16 weeks of LIALDA treatment.
Researchers found a genetic change in the dopamine transporter protein that makes it behave as if amphetamine is present, leading to altered dopamine signaling and contributing to ADHD symptoms. The altered function supports a role for dopamine signaling in the disease.
A new training program has been shown to improve the diagnosis and treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in school-aged children. The program, developed by Cincinnati Children's Hospital Medical Center, focused on implementing standardized evidence-based guidelines for ADHD diagnosis and treatment.
A study found that Ritalin works in the prefrontal cortex to enhance cognition and focus, while having limited effects elsewhere. The medication tunes neuron sensitivity to signals, leading to improved cognitive function and attention.
A long-term safety study on Lialda found that the medication is generally well-tolerated, with most adverse events being mild or moderate in intensity. The study also showed that a majority of patients remained in remission for 12 months.
A study by researchers from UWM found that a specific version of the DRD4 gene appears to have different effects depending on one's environment. In nomadic Ariaal men with the 7R allele variant, this gene is linked to better health and nourishment.
A study published in JAMA found that St. John's wort did not improve ADHD symptoms in children and adolescents. The trial involved 54 participants who received either St. John's wort or a placebo for eight weeks, with no significant differences in symptom improvement.
A study of Kenyan nomads found that an ADHD-associated gene variant is linked to better health in the nomadic population, but malnourishment in settled individuals. This suggests that behavior differences associated with ADHD may be more or less effective depending on the environment.
A study found that students who slept less than eight hours per night had lower GPAs and were more likely to experience emotional disturbances. The research suggests that getting enough sleep is crucial for adolescents' psychological functioning and can have serious consequences.
Research published in Occupational and Environmental Medicine reveals that individuals with ADHD complete 1 month's worth of work in a year. Employers may benefit from implementing workplace screening programs to support affected workers, as effective treatments can improve performance.
A phase III pivotal study showed VYVANSE significantly improved ADHD symptoms in adults, including inattention and hyperactivity. The medication provided a 43% reduction in ADHD Rating Scale (ADHD-RS-IV) scores and was associated with a 60% improvement rate on the Clinical Global Impressions-Improvement (CGI-I) scale.
A new data analysis confirms DAYTRANA's effectiveness in controlling ADHD symptoms in both boys and girls for up to 12 months. The study found that children with ADHD experienced significant improvements in symptom control, with lower scores on the ADHD Rating Scale.
INTUNIV, a selective alpha-2A receptor agonist, demonstrated significant efficacy in reducing ADHD symptoms across all measured time points up to 24 hours postdose. The medication showed improved symptoms of ADHD in patients treated with INTUNIV compared to those receiving placebo.
Shire will present efficacy and safety results for its ADHD treatments, including lisdexamfetamine dimesylate, methylphenidate transdermal system, and guanfacine extended release. The presentations aim to contribute to the growing body of research on ADHD treatment options.
Sleep problems are extremely common in children with ADHD, associated with poorer child psychosocial quality of life and caregiver mental health. The prevalence of mild to moderate sleep problems was found to be significant, with difficulties falling asleep and resisting bedtime being common symptoms.
A study examines childhood ADHD in underrepresented minorities, highlighting obstacles faced by families and providing recommendations for assessment and treatment. Effective treatments exist, but many minority children lack culturally sensitive assessments, potentially leading to devastating results.
Adolescent girls with ADHD are more likely to develop body-image dissatisfaction and binge-eating behaviors, according to a new study. The study found that these girls may be at risk for eating disorders, depression, and anxiety due to impulsive behaviors.
A new study found that stimulant treatment for children with ADHD has no effect on their future risk of substance abuse. The 10-year follow-up study analyzed over 100 young men and controlled for conditions like conduct disorder, which are associated with substance abuse.
A new study found that methylphenidate treatment improved sleep parameters in adults with ADHD, including increased sleep efficiency and a feeling of improved restorative value. The study also showed that objective and subjective sleep problems in adults with ADHD are identical to those in children with ADHD.
A new UCLA study found that only half of children diagnosed with ADHD exhibit cognitive defects, challenging the common method for diagnosing the disorder. The research also suggested that medication is not always effective in treating ADHD, highlighting the need for alternative approaches to address long-term problems.
A new study predicts a 10-fold increase in ADHD prescription costs for the NHS, rising from £7m to £49-101m by 2012. The research modelled various scenarios and considered factors such as drug availability, diagnosis rates, and treatment levels.
Youth with ADHD exhibit delayed brain maturation in frontal cortex areas, which can affect higher-order executive control functions. However, the delay is most pronounced in regions at the front of the brain's outer mantle, supporting ability to control thinking, attention, and planning.